Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Rituximab 82venetoclax 56ibrutinib 46obinutuzumab 43Bendamustine Hydrochloride 40idelalisib 30Cyclophosphamide 29acalabrutinib 28fludarabine 27Chlorambucil 27pirtobrutinib 18ublituximab 16ofatumumab 16zanubrutinib 14umbralisib 14Lenalidomide 11fludarabine phosphate 9Alemtuzumab 9navitoclax 7duvelisib 7Azacitidine 5lumiliximab 4aflibercept 4TRU 016 4Interleukin-2 4BI 836826 4ARQ531 4tafasitamab 3motexafin gadolinium 3dinaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Lymphocytic, Chronic, B-Cell × GNKG168 × Clear all
NCT01035216 2014-12-23

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)

SBI Biotech Co., Ltd.

Phase 1 Terminated
18 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡